EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Public Health Benefits of Applying Evidence-Based Best Practices in Managing Patients Hospitalized for COVID-19

Andre C Kalil iD, Aastha Chandak iD, Luke S P Moore iD, Neera Ahuja iD, Martin Kolditz iD, Roman Casciano iD, Ananth Kadambi iD, Mohsen Yaghoubi, Sotirios Tsiodras iD, Jakob J Malin iD, Essy Mozaffari, Michele Bartoletti iD

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae517 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Andre C Kalil und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Alanine, Hospitalization, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As coronavirus disease 2019 (COVID-19)–related mortality remains a concern, optimal management of patients hospitalized for COVID-19 continues to evolve. We developed a population model based on real-world evidence to quantify the clinical impact of increased utilization of remdesivir, the effectiveness of which has been well established in hospitalized patients with COVID-19.

Methods

The PINC AI healthcare database records for patients hospitalized for COVID-19 from January to December 2023 were stratified by those treated with or without remdesivir (“RDV” and “no RDV”) and by supplemental oxygen requirements: no supplemental oxygen charges (NSOc), low-flow oxygen (LFO), and high-flow oxygen/non-invasive ventilation. Key vulnerable subgroups such as elderly and immunocompromised patients were also evaluated. The model applied previously published hazard ratios (HRs) to 28-day in-hospital mortality incidence to determine the number of potential lives saved if additional no RDV patients had been treated with remdesivir upon hospital admission.

Results

Of 84 810 hospitalizations for COVID-19 in 2023, 13,233 no RDV patients were similar in terms of characteristics and clinical presentation to the RDV patients. The model predicted that initiation of remdesivir in these patients could have saved 231 lives. Projected nationally, this translates to >800 potential lives saved (95% confidence interval, 469–1126). Eighty-nine percent of potential lives saved were elderly and 19% were immunocompromised individuals. Seventy-six percent were among NSOc or LFO patients.

Conclusions

This public health model underscores the value of initiating remdesivir upon admission in patients hospitalized for COVID-19, in accordance with evidence-based best practices, to minimize lives lost because of severe acute respiratory syndrome coronavirus 2 infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine MonophosphateAlanineHospitalizationCOVID-19Antiviral AgentsSARS-CoV-2COVID-19 Drug TreatmentHumansFemaleMaleAgedMiddle AgedPublic HealthHospital MortalityAged, 80 and overAdultEvidence-Based Practice

Stichwörter der Autor:innen

COVID-19 modelSARS-CoV-2data sciencedexamethasonemortalityreal world dataremdesivir

Substanzen

remdesivirAdenosine MonophosphateAlanineAntiviral Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Evidence and Access, Certara, New York, New York, USA.
  • Department of Infectious Diseases, Imperial College, London, United Kingdom.
  • Department of Internal Medicine, Stanford University School of Medicine, Stanford, California, USA.
  • Medical Department I, Division of Pulmonology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
  • Professor of Medicine and Infectious Diseases, National & Kapodistrian University of Athens Medical School, Chair, 4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece.

ORCID-Profile: Andre C Kalil, Aastha Chandak, Luke S P Moore, Neera Ahuja, Martin Kolditz, Roman Casciano, Ananth Kadambi, Sotirios Tsiodras, Jakob J Malin, Michele Bartoletti

Förderung

  • Gilead Sciences

Zitieren

APA

Kalil, A. C., Chandak, A., Moore, L. S. P., Ahuja, N., Kolditz, M., Casciano, R., Kadambi, A., Yaghoubi, M., Tsiodras, S., Malin, J. J., Mozaffari, E., & Bartoletti, M. (2024). Public Health Benefits of Applying Evidence-Based Best Practices in Managing Patients Hospitalized for COVID-19. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae517

Vancouver

Kalil AC, Chandak A, Moore LSP, Ahuja N, Kolditz M, Casciano R, et al. Public Health Benefits of Applying Evidence-Based Best Practices in Managing Patients Hospitalized for COVID-19. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae517

BibTeX
@article{Kalil2024,
  author = {Kalil, Andre C and Chandak, Aastha and Moore, Luke S P and Ahuja, Neera and Kolditz, Martin and Casciano, Roman and Kadambi, Ananth and Yaghoubi, Mohsen and Tsiodras, Sotirios and Malin, Jakob J and Mozaffari, Essy and Bartoletti, Michele},
  title = {Public Health Benefits of Applying Evidence-Based Best Practices in Managing Patients Hospitalized for COVID-19},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae517}
}
Kostenlos starten →